Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation) - 28/02/15
, Arnoud W.J. van't Hof, MD b, C. Michael Gibson, MD c, Donald Cutlip, MD d, Uwe Zeymer, MD e, Marko Noc, MD f, Mauro Maioli, MD g, Simona Zorman, MD f, H. Mesquita Gabriel, MD h, Ayse Emre, MD i, Tomasz Rakowski, MD j, Maryann Gyongyosi, MD k, Kurt Huber, MD l, Francesco Bellandi, MD g, Dariusz Dudek, MD jon behalf of the
EGYPT cooperation
Abstract |
Contrasting data have been so far reported on facilitation with glycoprotein IIb-IIIa inhibitors (GpIIbIIIa) in patients who underwent primary percutaneous coronary intervention. However, it has been demonstrated a time-dependent composition of coronary thrombus in ST-segment elevation myocardial infarction, with more platelets in the first hours. Subsequently, the benefits of early administration of GpIIbIIIa may be affected by the time from symptoms onset to GpIIbIIIa, that therefore is the aim of this study. Our population is represented by 814 patients who underwent GpIIbIIIa facilitated primary angioplasty included in the Early glycoprotein IIb-IIIa inhibitors in primary angioplasty database. Patients were divided according to quartiles of time from symptom onset to GpIIbIIIa administration (≤65 minutes; 65 to 100 minutes; 101 to 178 minutes; and >178 minutes). Myocardial perfusion was evaluated by myocardial blush grade and ST-segment resolution. Time from symptoms onset to GpIIbIIIa was linearly associated with hypertension, diabetes, hypercholesterolemia, and previous myocardial infarction but inversely associated with smoking. Abciximab was more often administrated later from symptoms onset. Time from symptoms onset to GpIIbIIIa was significantly associated with the rate of preprocedural recanalization (thrombolysis in myocardial infarction [TIMI] 2 to 3; p <0.001), postprocedural TIMI 3 flow (p <0.001), the rate of complete ST-segment resolution (p <0.001), and the rate of myocardial blush grade 2 to 3 (p <0.001) and inversely associated with the occurrence of distal embolization (p <0.001). Follow-up data were collected at a median (twenty-fifth to seventy-fifth) of 360 (30 to 1,095) days. A total of 52 patients had died. Time to GpIIbIIIa had a significant impact on mortality (hazard ratio [95% confidence interval] 1.46 [1.11 to 1.92], p = 0.007) that was confirmed after correction for baseline confounding factors (adjusted hazard ratio [95% confidence interval] 1.41 [1.02 to 2.21], p = 0.042). In conclusion, this study showed that in patients who underwent primary angioplasty with upstream GpIIbIIIa, time from symptoms onset to GpIIbIIIa strongly impacts on preprocedural recanalization, distal embolization, myocardial perfusion, and long-term survival.
Le texte complet de cet article est disponible en PDF.Plan
| See page 714 for disclosure information. |
Vol 115 - N° 6
P. 711-715 - mars 2015 Retour au numéro
Article précédent
- Effect of a Shortened-Duration Eptifibatide Infusion (75 mg) as Adjunctive Therapy for Percutaneous Coronary Intervention on Inhospital Cardiovascular Outcomes and Bleeding
- Scott D. Nei, Jeffrey J. Armon, Ross A. Dierkhising, Malcolm R. Bell, Verghese Mathew, Gregory W. Barsness, Narith N. Ou
- Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity
- Thibault Lhermusier, Michael J. Lipinski, Udaya S. Tantry, Ricardo O. Escarcega, Nevin Baker, Kevin P. Bliden, Marco A. Magalhaes, Hideaki Ota, Wenjie Tian, Lakshmana Pendyala, Saar Minha, Fang Chen, Rebecca Torguson, Paul A. Gurbel, Ron Waksman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?